Keyhole limpet hemocyanin: an effective adjunct against melanoma in vivo

American Journal of Surgery

Volumn 194, Issue 5, 2007, Pages 628-632

  Rizvi, Irfan ^a   Riggs, Dale R ^a   Jackson, Barbara J ^a   McFadden, David W ^a  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Immunotherapy; In vivo; Keyhole limpet hemocyanin; Melanoma

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER INHIBITION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFECT; FEMALE; IN VIVO STUDY; MELANOMA; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CELL LINE, TUMOR; FEMALE; HEMOCYANIN; INTERFERON-ALPHA; INTERLEUKIN-2; MELANOMA; MICE; SKIN NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 35148814801     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2007.08.005     Document Type: Article

References (23)

1. Jemal A., Siegal R., Ward E., et al. Cancer Statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
2. McGillis S.T., and Fein H. Topical treatment strategies for non-melanoma skin cancer and precursor lesions. Semin Cutan Med Surg 23 (2004) 174-183
3. Villa A.M., and Berman B. Immunomodulators for skin cancer. J Drugs Dermatol 3 (2004) 533-539
4. Harris J.R., and Markl J. Keyhole limpet hemocyanin: Molecular structure of a potent marine immunoactivator. A review. Eur Urol 37 suppl 3 (2000) 24-33
5. Harris J.R., and Markl J. Keyhole limpet hemocyanin (KLH): a biomedical review. Micron 30 (1999) 597-623
6. Olsson C.A., Chute R., and Rao C.N. Immunologic reduction of bladder cancer recurrence rate. J Urol 111 (1974) 173-176
7. Riggs D.R., Tarry W.F., DeHaven J.I., et al. Immunotherapy of murine transitional cell carcinoma of the bladder using alpha and gamma interferon in combination with other forms of immunotherapy. J Urol 147 (1992) 212-214
8. Jurincic C.D., Engelmann U., Gasch J., et al. Immunotherapy in bladder cancer with keyhole-limpet hemocyanin: a randomized study. J Urol 139 (1988) 723-726
9. Jurincic-Winkler C.D., Metz K.A., Beuth J., et al. Keyhole limpet hemocyanin for carcinoma in situ of the bladder: a long-term follow-up study. Eur Urol 37 suppl 3 (2000) 45-49
10. Lamm D.L., DeHaven J.I., and Riggs D.R. Keyhole limpet hemocyanin immunotherapy of bladder cancer: laboratory and clinical studies. Eur Urol 37 suppl 3 (2000) 41-44
11. Riggs D., Jackson B., Vona-Davis L., et al. In vitro anticancer effects of a novel immunostimulant: keyhole limpet hemocyanin. J Surg Res 108 (2002) 279-284
12. Somasundar P., Riggs D.R., Jackson B.J., et al. Inhibition of melanoma growth by hemocyanin occurs via early apoptotic pathways. Am J Surg 190 (2005) 713-716
13. Riggs D.R., Jackson B.J., Vona-Davis L., et al. In vitro effects of keyhole limpet hemocyanin in breast and pancreatic cancer in regards to cell growth, cytokine production, and apoptosis. Am J Surg 189 (2005) 680-684
14. McFadden D.W., Riggs D.R., Jackson B.J., et al. Keyhole limpet hemocyanin, a novel immune stimulant with promising anticancer activity in Barrett's esophageal adenocarcinoma. Am J Surg 186 (2003) 552-555
15. Vona-Davis L., Vincent T., Zulfiqar S., et al. Proteomic analysis of SEG-1 human Barrett's-associated esophageal adenocarcinoma cells treated with keyhole limpet hemocyanin. J Gastrointest Surg 8 (2004) 1018-1023
16. Kirkwood J.M., Strawderman M.H., Ernstoff M.S., et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol 14 (1996) 7-17
17. Atkins M.B., Lotze M.T., Dutcher J.P., et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17 (1999) 2105-2116
18. McFadden D.W., Riggs D.R., Jackson B.J., et al. Keyhole limpet hemocyanin potentiates standard immunotherapy for melanoma. Am J Surg 193 (2007) 284-287
19. Ludbrook J. Multiple comparison procedures updated. Clin Exp Pharmacol Physiol 25 (1998) 1032-1037
20. Dixon W.J., and Massey F.J. Introduction to Statistical Analysis. 4th ed. (1983), McGraw-Hill, New York
21. Kirkwood J.M., Ibrahim J., Lawson D.H., et al. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group phase II trial E2696. J Clin Oncol 19 (2001) 1430-1436
22. Eggermont A.M., Suciu S., Mackie R., et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomized controlled trial. Lancet 366 (2005) 1189-1196
23. Rizvi I., Riggs D.R., Jackson B.J., et al. Inositol hexaphosphate (IP6) inhibits cellular proliferation in melanoma. J Surg Res 133 (2006) 3-6